載入...
Anti–CTLA-4 therapy requires an Fc domain for efficacy
Ipilimumab, a monoclonal antibody that recognizes cytotoxic T lymphocyte antigen (CTLA)-4, was the first approved “checkpoint”-blocking anticancer therapy. In mouse tumor models, the response to antibodies against CTLA-4 depends entirely on expression of the Fcγ receptor (FcγR), which may facilitate...
Na minha lista:
| 發表在: | Proc Natl Acad Sci U S A |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
National Academy of Sciences
2018
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5899492/ https://ncbi.nlm.nih.gov/pubmed/29581255 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.1801524115 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|